Boston Scientific announced it has received FDA approval for the Agent Drug-Coated Balloon, or DCB, which is indicated to treat coronary in-stent restenosis, or ISR, in patients with coronary artery disease. ISR is the obstruction or narrowing of a stented vessel by plaque or scar tissue.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BSX:
- Wells upgrades Edwards Lifesciences, says tricuspid opportunity underappreciated
- Boston Scientific price target raised to $70 from $60 at Barclays
- Qualcomm downgraded, Cigna upgraded: Wall Street’s top analyst calls
- Boston Scientific price target raised to $63 from $55 at Deutsche Bank
- Boston Scientific price target raised to $73 from $70 at Truist